New research from the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators says that artificial intelligence (AI) could serve as a personalized treatment tool for cancer patients.
To test their hypothesis, the researchers analyzed “the largest dataset of lung adenocarcinoma pathology slides matched with next-generation sequencing results from multiple institutions across the United States and Europe.” Additionally, they “trained their AI on H&E-stained pathology slides.” They hoped to provide patients with a more cost-effective testing option and expand access to care.
The study revealed “that AI can accurately predict genetic mutations from routine pathology slides—potentially reducing the need for rapid genetic testing in certain cases.” Specifically, the AI predicted EGFR, according to Mount Sinai.
The study is published in Nature Medicine.
